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Abstract
Parthenogenetic stem cells (PSCs) are a promising candidate donor for cell therapy appli-
cations. Similar to embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs),
PSCs exhibit self-renewing capacity and clonogenic proliferation in vitro. PSCs exhibit
largely haploidentical genotype, and as such may constitute an attractive population for allo-
genic applications. In this study, PSCs isolated from transgenic mice carrying a cardiomyo-
cyte-restricted reporter transgene to permit tracking of donor cells were genetically modified
to carry a cardiomyocyte-restricted aminoglycoside phosphotransferase expression cas-
sette (MHC-neor/pGK-hygror) to permit the generation of highly enriched cardiomyocyte cul-
tures from spontaneously differentiating PSCs by simple selection with the neomycin
analogue G148. Following engraftment into isogenic recipient hearts, the selected cardio-
myocytes formed a functional syncytium with the host myocardium as evidenced by the
presence of entrained intracellular calcium transients. These cells thus constitute a potential
source of therapeutic donor cells.
Introduction
Acute myocardial infarction commonly results in the loss of large numbers of cardiomyocytes.
Considerable effort has been invested in developing strategies to repair myocardial damage,
including the direct injection of donor cardiomyocytes [1,2] as well as the generation and
implantation of bioengineered patches, including two dimensional sheets of cells [3] as well as
three dimensional constructs [4]. Initial proof of concept studies utilized fetal cardiomyocytes
[1], which were followed shortly by embryonic stem cell (ESC)-derived cardiomyocytes [5].
More recently, donor human ESC-derived cardiomyocytes were shown to functionally engraft
monkey hearts with small experimentally induced infarcts. Induced pluripotent stem cells
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(iPSCs) also give rise to functional cardiomyocytes which can be successfully engrafted into
donor hearts [6]. Thus, there is mounting evidence that delivery of exogenous cardiomyocyte
donor cells can successfully engraft, and in some cases, improve function in damaged hearts.
Chemical stimulation of mammalian ova can give rise to diploid cells which are capable of
forming blastocysts in vitro [7]. When cultured under appropriate conditions, these blastocysts
can give rise to ESC-like cells designated parthenogenetic stem cells (PSCs). We have recently
shown that PSCs give rise to bona fide cardiomyocytes following delivery into host blastocysts,
and following either spontaneous or cytokine-directed differentiation in vitro [8]. Moreover,
PSC-derived cardiomyocytes derived via directed differentiation can stably engraft following
intra-cardiac injection, as well as form functional three dimensional tissue constructs in vitro
which survive following surgical attachment to damaged hearts [8]. Because PSCs exhibit a
largely haploidentical genotype, it is conceivable that a limited panel of donor cells would be
sufficient for “off the shelf” allogenic applications, a highly desirable characteristic for potential
clinical application.
We have previously shown that highly enriched populations of cardiomyocytes can be read-
ily generated using ESCs carrying a transgene comprised of the lineage-restricted cardiac myo-
sin heavy chain (MHC) promoter and sequences encoding aminoglycoside phosphotransferase
[5]. Treatment of spontaneously differentiating cultures of ESCs carrying this cardiomyocyte
selection cassette with the neomycin analogue G418 gave rise to cultures comprised of>99%
cardiomyocytes. When amplified in bioreactor, 100s of millions of cells were readily generated
[9,10]. In this study, PSCs carrying a cardiomyocyte-restricted enhanced green fluorescence
protein (EGFP) reporter transgene as well as the cardiomyocyte selection cassette were
employed to demonstrate that highly purified cardiomyocyte cultures could readily be gener-
ated. Importantly, these cells formed a functional syncytium with the host myocardium follow-
ing engraftment into adult recipient hearts.
Materials and Methods
PSC culture
We used PSCs (A3 line; generated by M.D. and P.C. in the Zimmermann lab) from mice carry-
ing an MHC-EGFP reporter transgene [8]. These cells were derived from [C57Bl/6J x DBA/2J]
F1 mice. The MHC-EGFP reporter targets EGFP expression specifically to cardiomyocytes
[11]. The PSC cells were maintained on freshly prepared STO feeder layer in maintenance
medium consisting of high glucose DMEM, supplemented with 15% fetal bovine serum (FBS;
Invitrogen, Carlsbad, CA, USA), 100 U/ml LIF, 2 mM L-glutamine, 1% non-essential amino
acid (NEAA), 0.1 mM β-mercaptoethanol, 1% sodium pyruvate (Sigma, St. Louis, MO, USA),
25 mMHEPES (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin. To facilitate collec-
tion of PSCs for downstream studies, a feeder-free culture condition was optimized, i.e., STO
cell-conditioned maintenance medium (CM) was collected and applied to PSC cultures after
dilution with fresh maintenance medium at different ratios (25%, 50%, 75% and no dilution
designated to 100%; data derived from four individual experiments of 12 replicate studies).
Transfection of MHC-EGFP PSCs with the transgene MHC-neor/pGK-
hygror
A bicistronic cassette comprising an α-cardiac myosin heavy chain-aminoglycoside phospho-
transferase (MHC-neor) and a phosphoglycerate kinase (pGK)-hygromycin resistant transgene
(pGK-hygror) on a common pBM20 vector backbone (Boehringer Mannheim, Indianapolis,
IN, USA) was described previously [5]. This construct, designatedMHC-neor/pGK-hygror was
PSC-Derived Cardiomyocytes
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introduced into MHC-EGFP PSCs via electroporation. To optimize the electroporation volt-
age, initial studies applied a constitutively expressed ds-Red transgene (which could be visual-
ized via epifluorescence) to PSCs. Briefly, PSCs at 1 × 107 in 1 ml 25 mMHEPES were
electroporated in the presence of 25 ng ds-Red transgene (Bio-Rad MicroPulser, Hercules, CA,
USA). The voltage for electroporation was optimized in terms of transfection efficiency (as
reflected by percent of red cells versus all attached cells) and cell viability (data derived from
four individual experiments of 8 replicate studies). Subsequently, PSCs at 1 × 107 in 1 ml
25 mMHEPES were electroporated with 25 ngMHC-neor/pGK-hygror under the optimized
voltage. Three days after electroporation, PSCs were selected by hygromycin at 200 μg/ml in
optimally diluted STO-CM for 1 week, and independent lineages were derived.
Polymerase chain reaction (PCR) and Reverse Transcription-PCR
(RT-PCR)
PCR analysis was used to confirm the presence of MHC-EGFP and MHC-neor/pGK-hygror
transgenes and RT-PCR analysis to confirm expression of stemness genes. Total DNA and
RNA were extracted by the TRIzol Reagent (Invitrogen), according to the manufacturer’s
instructions. The extracted DNA or cDNA generated via reverse transcription reaction
(RNeasy extraction mini kit; Qiagen, Hilden, Germany) were subjected to PCR analysis as indi-
cated in Table 1.
Spontaneous differentiation and G418 selection
To induce differentiation, PSCs were cultured in induction medium consisting of IMEM sup-
plemented with 20% FBS, 1% NEAA, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol and
0.5 mM ascorbic acid (Sigma). Hanging drop culture [12] was conducted for 5 days, followed
by adherent culture for another 5 days (“5+5 process”; initiated by optimization of hanging
drop input number in four individual experiments of 12 replicate studies). Subsequently, G418
selection was conducted at 250 μg/ml in the induction medium for 2 weeks (Fig 1). To further
enhance drug selection, on day 13 (i.e. day 3 during G418 selection), the adherent colonies
were incubated with 2 ml digestion solution containing IMDM supplemented with 0.2% colla-
genase type II (Sigma) and 60 U/ml DNase I (Sigma) at 37°C for 1 hour. The resulting cell
clumps were collected and resuspended in 0.05% trypsin (Invitrogen) for further digestion for
5 min. Dissociated cells were then pelleted and replated into G418-supplemented induction
medium in 0.1% gelatin-coated dishes. During detection of EFGP+ cell purity in a time-
dependent manner, data were acquired in four individual experiments of 12 replicate studies.
Table 1. Primer sequences and product sizes of targeted genes
Target genes Forward (from 5´ to 3´) Reverse (from 5´ to 3´) Size (bp)
GAPDH GTGCTGAGTATGTCGTGGAG ATGCAGGGATGATGTTCTG 357
Oct-4 GGAAAGCAACTCAGAGGGAA TGTACCCCAAGGTGATCCTC 173
Nanog AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG 363
Nkx2.5 CAAGTGCTCTCCTGCTTTCC CTGTCGCTTGCACTTGTAGC 349
GATA-4 CTCCTACTCCAGCCCCTACC TAGTCTGGCAGTTGGCACAG 359
MHC AGTTCGACAAGATCGAGGACA GTGCCCTTGTTTGCATTAGG 400
MLC-2v TTCTCAACGCATTCAAGGTG TTCAGGGCTCAGTCCTTCTC 214
MHC-eGFP ATCGAGCTGAAGGGCATCGACTTCAAGGAG CTCCAGCAGGACCATGTGATCGCGCTTCTC 299
MHC-neor/pGK-hygror TCCTGCCGAGAAAGTATCCATCATGGCTGA ATTCGCCGCCAAGCTCTTCAGCAATATCAC 400
doi:10.1371/journal.pone.0131511.t001
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Cell transplantation
Animal care and all experimental procedures were performed in strict accordance with the
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of
Health (publication No. 85–23, revised 1996). The handling of mice and all experimental pro-
cedures were specifically approved for this study by the Institutional Animal Care and Use
Committee of Indiana University and Tongji University. For survival experiments, humane
endpoints were applied to this study. For heart sample collection, all the mice were sacrificed
by CO2 asphyxiation. All efforts were performed to minimize the distress and suffering of the
animals. Animals were anesthetized with inhalation of 3% halothane and maintained on 1.5%
halothane in 70% nitrous oxide and 30% oxygen. Cultures of PSC-derived cardiomyocytes
were digested with trypsin, washed thrice with PBS, and resuspended in the pro-survival cock-
tail consisting of 50% (v/v) growth factor-reduced Matrigel (BD Biosciences, Bedford, MA,
USA),100 mM ZVAD (benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethyl ketone; Cal-
biochem, San Diego, CA, USA), 50 nM Bcl-XL BH4 (cell-permeant TAT peptide, Calbiochem),
200 nM cyclosporine A (Novartis, Basel, Switzerland), 100 ng/ml IGF-1(Sigma) and 50 mM
pinacidil (Sigma) [13]. Cells at 5 × 104/recipient in 5 μl pro-survival cocktail solution were
directly injected into the left ventricular free wall of anesthetized, intubated [C57Bl/6J x DBA/
2J]F1 female siblings (with the age of 12 ± 1 weeks; weighing 28 ± 2 g; n = 23) using a 30-gauge
tuberculin syringe. After extubation and evacuation of the pneumothorax, mice were placed at
37°C and monitored in micro-isolator cages (one per cage) until they recovered from surgery.
Histology
Hearts were harvested, cryoprotected in 30% sucrose, embedded and sectioned at 10μm on a
cryomicrotome as described previously [1]. Nonspecific immunoreactivity was blocked by
incubation in 10% goat serum/1% bovine serum albumin in PBS. Sections were incubated with
anti-α-actinin antibody (A7811, clone EA-53, produced in mouse; 1:100 dilution; Sigma) and
immune reactivity was subsequently visualized using a rhodamine-conjugated secondary anti-
body (AP160R; 1:100; Millipore, Billerica, MA, USA). EGFP signal was visualized via
epifluorescence.
Imaging via 2-photon laser scanning fluorescent microscopy (TPLSM)
Images were recorded with an Olympus FV1000 Laser Scanning microscope. Illumination for
2-photon excitation was provided by a mode-locked Ti/Sapphire laser (Spectraphysics, Moun-
tain View, CA, USA) and the excitation wave length was 810 nm. Hearts were imaged through
Fig 1. Schematic diagram of differentiation of parthenogenetic stem cells and cardiomyocyte enrichment.
doi:10.1371/journal.pone.0131511.g001
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a Nikon 1.2 numerical aperture water-immersion lens with a working distance of 200 μm.
Emitted light was collected by 2 photomultiplier tubes fitted with narrow bandwidth filters for
560–650 nm and 500–550 nm, respectively. Images were collected at a resolution of 0.21 to
0.43 μm/pixel along the x–y-axis. For line-scan mode analysis, hearts were scanned repetitively
along a line spanning EGFP-host and EGFP+ donor cardiomyocytes. Line-scan images were
then constructed by stacking all lines vertically. Post-acquisition analysis was performed with
MetaMorph software version 4.6r (Universal Imaging Incorporation, Downingtown, PA,
USA). For determination of the time course of [Ca2+]i decay, rhod-2 fluorescence intensity was
normalized to the difference between peak and baseline intensity.
Statistical analysis
Data are presented as mean ± standard deviation. Normality test, one way ANOVA and the
SNK test were applied to pairwise comparison. The software SPSS 17.0 (SPSS Inc., Chicago, IL,
USA) was used and p-values< 0.05 were considered statistically significant.
Results
Optimization of feeder-free conditions and electroporation voltage
PSCs were grown onto STO cell feeder layers. As indicated, 50% STO-CM supplementation
was shown to allow efficient maintenance of undifferentiated status of PSCs with highest cell
viability (Fig 2a and 2b). Electroporation conditions were next optimized. PSCs were electropo-
rated with a ubiquitously-expressed ds-Red reporter transgene, and transfection efficiency was
calculated by the percent of ds-Red+ cells vs. the number of attached cells 24 h after electropo-
ration. Electroporation at 180 V gave optimal results, with over 70% cell viability and over 30%
Fig 2. Characterization of growth and transfection efficiency of parthenogenetic stem cells (PSCs). (a,
b) Effects of STO-conditioned medium (CM) on maintaining undifferentiated status (a; n = 12) and cell viability
of PSCs (b; n = 12) after 2 days’ culture. (c) Viability and transfection efficiency of PSCs under electroporation
at different voltages (n = 8). Results were evaluated according to ds-Red expressing reporter.
doi:10.1371/journal.pone.0131511.g002
PSC-Derived Cardiomyocytes
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transfection efficiency (Fig 2c). Higher voltage resulted in higher transfection efficiency at the
cost of cell viability.
Generation and characterization of MHC-neor/pGK-hygror PSC cells
Using conditions as optimized above, PSCs derived from the MHC-EGFP mice were trans-
fected with the MHC-neor/pGK-hygror construct. After hygromycin selection for 1 week, sur-
viving colonies were picked for further propagation, and subject to serial passages. As expected,
the sequences from the MHC-neor/pGK-hygror were readily detected in the hygromycin-
selected cultures (7 MHC-neor/pGK-hygror PSC sublines were generated as illustrated in Fig
3a; data for subline #4 are shown in Fig 3b). The hygromycin selected clones exhibited robust
expression of Oct-4 and Nanog (Fig 3c). PSC differentiation was induced in hanging drop cul-
tures (Fig 3d). Input cell content was optimized in terms of cell viability and frequency of cardi-
omyogenic differentiation (as evidenced by the presence of beating colonies) at day 10; an
input of 500 cells per drop was optimal (Fig 3e and 3f).
Genetic selection of PSC-derived cardiomyocytes
PSC subline #4 was cultured in hanging drops for 5 days, followed by adherent culture for
another 5 days. G418 selection was then imposed. RT-PCR analyses revealed a progressive
decrease in Oct-4 and Nanog expression, consistent with the differentiation of the cells (Fig
4a). A concomitant increase in the expression of the cardiomyogenic lineage determining
genes Nkx2.5 and GATA4, followed by expression of the sarcomeric protein genes MHC and
MLC-2v, was also apparent. Co-induction of EGFP epifluorescence (from the MHC-EGFP
reporter) and α-actinin immune reactivity was readily apparent (Fig 4b). Expression of the
MHC-EGFP reporter was used to quantitate cardiomyocyte content following G418 selection.
Cultures of selected cardiomyocytes were dispersed into individual cells and replated in the
presence of G418 (Fig 5a). A progressive increase in cardiomyocyte content was apparent (Fig
5b–5f).
Engrafted PSC-derived cardiomyocytes obtained via genetic selection
form a functional syncytium with the host myocardium
PSC-derived cardiomyocytes obtained by G418 selection were injected into the left ventricular
free wall of [C57Bl/6J x DBA/2J]F1 mice (the genetic background of the mice originally used
for PSC derivation). Hearts were harvested two weeks later, and processed for immune histo-
logic analysis. Donor cardiomyocytes were readily detected by EGFP epifluorescence, and
exhibit a typical rod-shaped morphology (Fig 6a). Anti-α-actinin immune fluorescence indi-
cated that the donor cardiomyocytes had well developed myofibers which were aligned in par-
allel with those in the host cardiomyocytes (Fig 6b and 6c). TPLSM revealed the presence of
synchronous action potential-evoked calcium transients in the EGFP+ donor cell and its adja-
cent EGFP-host cardiomyocytes (Fig 6d–6f). Line averages as a function of time for a donor-
derived, EGFP-expressing myocyte and their neighboring, non-expressing host cardiomyo-
cytes revealed that the calcium transients in the donor cell were entrained by the electrical
activity of the recipient myocardium both during sinus rhythm and during electrical pacing at
3 Hz (Fig 6e). Further, the calcium transient kinetics in the donor and host myocyte was indis-
tinguishable from each other (Fig 6f). Overall, these results suggest that the transplanted PSC-
derived cardiomyocytes were structurally and functionally mature, and were electrically cou-
pled with the host cardiomyocytes.
PSC-Derived Cardiomyocytes
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Discussion
We have previously shown that PSCs derived from mice carrying an MHC-EGFP reporter
transgene can differentiate into cardiomyocytes in vitro and in vivo, and furthermore that PSC-
derived cardiomyocytes isolated via directed differentiation could be functionally engrafted
into recipient hearts [8]. In this study, we extend these observations and show that genetically
modified PSCs could be easily generated and used to produce essentially pure populations of
cardiomyocytes via simple G418 selection of spontaneously differentiating cultures. Moreover,
Fig 3. Transfection of PSCs with the MHC-neor/pGK-hygror construct. (a) After hygromycin selection for
1 week, 7 MHC-neor/pGK-hygror PSC sublines were generated. As indicated by PCR, PSC subline #4 and
subline #7 exhibited stable integration of MHC-neor and MHC-EGFP in the genome. (b) Even after
consecutive passages, PCR analysis showed stable integration of the MHC-neor and MHC-EGFP in the
genome of PSC subline #4. (c) RT-PCR showed that PSC subline #4 retained robust expression of Nanog
andOct4 transcript after passages, at levels similar to the parental cells. (d) Schematic diagram of the
cardiac induction protocol. (e, f) Cell viability (e; n = 12) and frequency of cardiomyogenic differentiation (f;
n = 12) in embryoid bodies (EBs) with initially variable cell input of PSC subline #4. The PSCs were cultured
for 10 days (as illustrated in d, 5 days’ hanging drop culture followed by 5 days’ adhesive culture, also
designated as “5+5 process”). * p < 0.05 vs. any other group.
doi:10.1371/journal.pone.0131511.g003
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the selected PSC-derived cardiomyocytes functionally integrate with the host myocardium fol-
lowing engraftment.
Many forms of cardiac disease have as a common endpoint, i.e., cardiomyocyte loss, and
therapeutically restoring cardiac mass is likely to be beneficial. The notion of cell transplanta-
tion for myocardial repair was initially introduced during the early 1990s, and donor cells from
these early studies included bona fide cardiomyocytes [1,14], ESC-derived cardiomyocytes
[5,15], and a plethora of adult-derived stem cells with varying degrees of cardiomyogenic activ-
ity [16]. Alternative strategies to restore cardiac mass in damaged hearts include induction of
cardiomyocyte proliferation [17–19], as well as directed trans-differentiation of resident non-
Fig 4. Cardiomyogenic differentiation and selection of PSCs. (a) RT-PCR analysis for stemness markers
(Oct-4 and Nanog) and cardiac lineage-specific markers (Nkx2.5, GATA-4, MHC, MLC-2v) through the
differentiation and selection processes. (b) Co-localization of EGFP and α-actinin immune reactivity
confirmed the cardiomyogenic identity of derived EGFP+ cells (at day 17).
doi:10.1371/journal.pone.0131511.g004
Fig 5. Cardiomyocyte enrichment. (a) Schematic diagram of enrichment process; (b-e) Progressive
enrichment of EGFP+ cardiomyocytes over time (as indicated) with G418 selection. (f) Purity of EGFP+
cardiomyocytes at day 13, day 17 and day 24 during G418 selection (n = 12).
doi:10.1371/journal.pone.0131511.g005
PSC-Derived Cardiomyocytes
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myocytes into cardiomyocytes [20,21]. Each approach has potential benefits and limitations,
with regards to efficacy and potential adverse side effects.
With regard to cell transplantation, many claims of adult-derived stem cells forming trans-
mural grafts have failed to be replicated by others [22–26]. While some controversy remains in
this field, the absence of reproducible overt cardiomyogenic activity raises concerns regarding
Fig 6. G418-selected PSC-derived cardiomyocytes are functionally integrated with the host
myocardium. (a) The presence of EGFP+ PSC-derived cardiomyocyte in the host heart at 2 weeks post
transplant. (b) α-actinin immunofluorescence of the same donor cell as in (a). (c) Merge of (a) and (b). (d-f)
Two-photon laser scanning microscopy revealed synchronous action potential-evoked calcium transients in
the EGFP+ donor cell and its adjacent EGFP-host cardiomyocytes. (d) 2-D images taken at 16-μm z-steps
across an EGFP+ donor (D) myocyte and its surrounding host (H) myocytes. The heart was being paced at a
frequency of 3 Hz during image acquisition. Periodic increases in rhod-2 fluoresence intensity reflect
increases in cytosolic calcium in response to propagating action potentials and span the entire width of the
image, including the EGFP+ donor cell. The dotted line denotes the position of the scan line for line-scan
imaging. (e) Line average as a function of time for the portions of the dotted scan line indicated by brackets in
(d). Line scans were obtained during spontaneous sinus rhythm and during electrical pacing at 3 Hz. Action
potential-evoked calcium transients in the host myocyte are in phase with those in the neighboring host
myocytes. (f) Superimposition of normalized calcium transients for the donor and host myocytes,
demonstrating similar kinetics of the transients in both cell types.
doi:10.1371/journal.pone.0131511.g006
PSC-Derived Cardiomyocytes
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the robustness of these cells to form large numbers of replacement cardiomyocytes. Thus while
these cells could impart benefit upon transplantation [27], it almost certainly arises indepen-
dently of donor cell cardiomyogenic activity. In light of this, transplantation of bona fide cardi-
omyocytes, derived from ESCs or ESC-like progenitors (i.e., iPSCs or PSCs) constitutes the
currently best validated source of donor cells which can restore muscle mass. With the notion
of allogenic application, PSCs have the distinct advantage that a comparatively small panel of
cells should give rise to donor cardiomyocytes which would be immunologically tolerated for
the vast majority of potential recipients, making PSCs a very attractive source for further
development.
The ability of PSCs to be easily modified genetically, and furthermore their ability to give
rise to highly enriched cardiomyocyte cultures capable of functional engraftments are an
important observation. Indeed, a recent proof-of-concept study demonstrated functional
engraftment of human ESC-derived cardiomyocytes into immune suppressed monkeys with
small cardiac infarcts [28]. These studies required further efforts to generate sufficient numbers
of donor cells for engraftment using directed differentiation approaches [29]. In contrast,
mouse ESCs carrying the MHC-neo selection cassette gave rise to large numbers of cardiomyo-
cytes using bioreactors [9,10]. Reproducible, economical and relatively fast large-scale genera-
tion of donor cells will be an important consideration for potential therapeutic applications.
In our previous studies, we have confirmed similar fundamental properties in murine PSCs
and ESCs, despite notable differences in allelic variability and differential imprinting character-
istics. Haploidentity of major histocompatibility complex in PSCs is particularly attractive for
allogeneic cell-based therapies and we have confirmed acceptance of PSCs in major histocom-
patibility complex-matched allotransplantation (8). The data presented here builds on our pre-
vious studies with murine PSCs, and demonstrates their genetic tractability, as well as the
ability to generate pure populations of cardiomyocytes using a relatively simple selection proto-
col with the transgenes of MHC-neor/pGK-hygror and MHC-EGFP. The utility of any source
of donor cardiomyocytes for cardiac repair will ultimately depend on their ability to effect
replacement of large areas of damaged myocardium. Future efforts will be directed towards
that end.
Supporting Information
S1 File. The completed form for Animal Research: Reporting In Vivo Experiments. The
ARRIVE Guidelines Checklist.
(DOCX)
Author Contributions
Conceived and designed the experiments: TYWHZ LJF. Performed the experiments: TY MR
MHSMD PC. Analyzed the data: TY MR LJF. Contributed reagents/materials/analysis tools:
TY MRWHZ LJF. Wrote the paper: TY LJF.
References
1. Soonpaa MH, Koh GY, Klug MG, Field LJ. Formation of nascent intercalated disks between grafted
fetal cardiomyocytes and host myocardium. Science. 1994; 264: 98–101. PMID: 8140423
2. LaflammeMA, Murry CE. Heart regeneration. Nature. 2011; 473: 326–335. doi: 10.1038/nature10147
PMID: 21593865
3. Sekine H, Shimizu T, Hobo K, Sekiya S, Yang J, Yamato M, et al. Endothelial cell coculture within
tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function
of ischemic hearts. Circulation. 2008; 118: S145–S152. doi: 10.1161/CIRCULATIONAHA.107.757286
PMID: 18824746
PSC-Derived Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0131511 June 25, 2015 10 / 12
4. ZimmermannWH, Melnychenko I, Wasmeier G, Didié M, Naito H, Nixdorff U, et al. Engineered heart tis-
sue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med. 2006; 12: 452–458.
PMID: 16582915
5. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating
embryonic stem cells form stable intracardiac grafts. J Clin Invest. 1996; 98: 216–224. PMID: 8690796
6. Kawamura M, Miyagawa S, Miki K, Saito A, Fukushima S, Higuchi T, et al. Feasibility, safety, and thera-
peutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ische-
mic cardiomyopathy model. Circulation. 2012; 126: S29–S37. PMID: 22965990
7. Cibelli JB, Grant KA, Chapman KB, Cunniff K, Worst T, Green HL, et al. Parthenogenetic stem cells in
nonhuman primates. Science. 2002; 295: 819–819. PMID: 11823632
8. Didié M, Christalla P, Rubart M, Muppala V, Döker S, Unsöld B, et al. Parthenogenetic stem cells for tis-
sue-engineered heart repair. J Clin Invest. 2013; 123: 1285–1298. doi: 10.1172/JCI66854 PMID:
23434590
9. Schroeder M, Niebruegge S, Werner A, Willbold E, Burg M, Ruediger M, et al. Differentiation and line-
age selection of mouse embryonic stem cells in a stirred bench scale bioreactor with automated pro-
cess control. Biotechnol Bioeng. 2005; 92: 920–933. PMID: 16189818
10. Zandstra PW, Bauwens C, Yin T, Liu Q, Schiller H, Zweigerdt R, et al. Scalable production of embryonic
stem cell-derived cardiomyocytes. Tissue Eng. 2003; 9: 767–778. PMID: 13678453
11. Rubart M, Pasumarthi KB, Nakajima H, Soonpaa MH, Nakajima HO, Field LJ. Physiological coupling of
donor and host cardiomyocytes after cellular transplantation. Circ Res. 2003; 92: 1217–1224. PMID:
12730096
12. Testa G, Tarantino C, Parisi S, Galizia G, Passaro F, Della-Morte D, et al. Serum withdrawal after
embryoid body formation does not impair cardiomyocyte development frommouse embryonic stem
cells. Cytotherapy. 2011; 13: 350–356. doi: 10.3109/14653249.2010.520311 PMID: 20873992
13. LaflammeMA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, et al. Cardiomyocytes
derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat
hearts. Nat Biotechnol. 2007; 25: 1015–1024. PMID: 17721512
14. Koh GY, SoonpaaMH, Klug MG, Pride HP, Cooper BJ, Zipes DP, et al. Stable fetal cardiomyocyte
grafts in the hearts of dystrophic mice and dogs. J Clin Invest. 1995; 96: 2034–2042. PMID: 7560097
15. LaflammeMA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, et al. Formation of humanmyocardium
in the rat heart from human embryonic stem cells. Am J Pathol. 2005; 167: 663–671. PMID: 16127147
16. Ye L, Haider HKh, Sim EK. Adult stem cells for cardiac repair: a choice between skeletal myoblasts and
bone marrow stem cells. Exp Biol Med (Maywood). 2006; 231: 8–19.
17. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2
results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res. 2005; 96:
110–118. PMID: 15576649
18. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, et al. p38 MAP kinase inhibition enables
proliferation of adult mammalian cardiomyocytes. Genes Dev. 2005; 19: 1175–1187. PMID: 15870258
19. Chen J, Huang ZP, Seok HY, Ding J, Kataoka M, Zhang Z, et al. mir-17-92 cluster is required for and
sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res. 2013; 112:
1557–1566. doi: 10.1161/CIRCRESAHA.112.300658 PMID: 23575307
20. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, et al. Direct reprogramming
of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010; 142: 375–386. doi: 10.
1016/j.cell.2010.07.002 PMID: 20691899
21. Huang GN, Thatcher JE, McAnally J, Kong Y, Qi X, TanW, et al. C/EBP transcription factors mediate
epicardial activation during heart development and injury. Science. 2012; 338: 1599–1603. doi: 10.
1126/science.1229765 PMID: 23160954
22. Murry CE, SoonpaaMH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, et al. Haematopoietic stem
cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428: 664–668.
PMID: 15034593
23. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem
cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004; 428: 668–673.
PMID: 15034594
24. Nygren JM, Jovinge S, Breitbach M, Säwén P, Röll W, Hescheler J, et al. Bone marrow-derived
hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdiffer-
entiation. Nat Med. 2004; 10: 494–501. PMID: 15107841
25. Zaruba MM, Soonpaa M, Reuter S, Field LJ. Cardiomyogenic potential of C-kit(+)-expressing cells
derived from neonatal and adult mouse hearts. Circulation. 2010; 121: 1992–2000. doi: 10.1161/
CIRCULATIONAHA.109.909093 PMID: 20421520
PSC-Derived Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0131511 June 25, 2015 11 / 12
26. van Berlo JH, Kanisicak O, Maillet M, Vagnozzi RJ, Karch J, Lin SC, et al. c-kit+ cells minimally contrib-
ute cardiomyocytes to the heart. Nature. 2014; 509: 337–341. doi: 10.1038/nature13309 PMID:
24805242
27. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in
patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet.
2011; 378: 1847–1857. doi: 10.1016/S0140-6736(11)61590-0 PMID: 22088800
28. Chong JJ, Yang X, Don CW, Minami E, Liu YW,Weyers JJ, et al. Human embryonic-stem-cell-derived
cardiomyocytes regenerate non-human primate hearts. Nature. 2014; 510: 273–277. doi: 10.1038/
nature13233 PMID: 24776797
29. Weng Z, Kong CW, Ren L, Karakikes I, Geng L, He J, et al. A simple, cost-effective but highly efficient
system for deriving ventricular cardiomyocytes from human pluripotent stem cells. Stem Cells Dev.
2014; 23(14): 1704–1716. doi: 10.1089/scd.2013.0509 PMID: 24564569
PSC-Derived Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0131511 June 25, 2015 12 / 12
